KB-1100

RC108-hIgG1

Background

c-Met is a receptor tyrosine kinase that activates a variety of different cell signaling pathways, including those related to proliferation, motility, migration, and invasion, by binding to its ligand, hepatocyte growth factor. RC108-hIgG1 is a recombinant, fully humanized, monovalent monoclonal antibody that binds the extracellular domain of MET, blocking interaction with HGF. This prevents activation of the MET signaling pathway, inhibiting the downstream events that lead to tumorigenesis.

Specifications

Catalog Number:
KB-1100
Cell Line Name:
RC108-hIgG1
Price:
0
Host Cell Line:
EXPI-CHO
Target:
Met
Species Reactivity:
Human
Application:
ELISA
Purification Method:
Affinity purified
Concentration:
>2mg/mL
Purity:
>95% by SDS-PAGE and SEC-HPLC
Endotoxin Level:
<0.5 EU/mg as determined by the LAL method
Sterility:
0.2μm filtered
Formulation:
20mM sodium citrate,150mM NaCl, pH5.5
Storage:
Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.
Bio Safety Level:
1
Validation:
SDS-PAGE | SEC-HPLC | ELISA

References

1. Donaghy H. Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates. MAbs. 2016;8(4):659–23. doi: 10.1080/19420862.2016.1156829. 2.Wang J, Anderson MG, Oleksijew A, Vaidya KS, Boghaert ER, Tucker L, Zhang Q, Han EK, Palma JP, Naumovski L, et al. ABBV-399, a c-Met Antibody-Drug Conjugate that Targets Both MET-Amplified and c-Met-Overexpressing Tumors, Irrespective of MET Pathway Dependence. Clin Cancer Res. 2017;23(4):992–1000.
Please enable JavaScript in your browser to complete this form.